Although 4-AP is primarily excreted in the urine as an unchanged drug and is thus not significantly metabolized by CYP enzymes11,20,21, it is important to determine if 4-AP may induce or inhibit CYP activity to further predict if drug–drug interactions may occur with the other drugs regularly used by MS patients. Here, PPIG is linked to myeloid sarcoma.